Dose Ranging, Switch Study of Islatravir (ISL) and MK-8507 Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- HIV -1 Infection
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Triple (Participant, Investigator, Outcomes Assessor)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Part 1 of the study is double-blind and at least 48 weeks in duration. Part 2 will commence once the dose is confirmed based on data through Week 48 from all participants in Part 1. In Parts 2 and 3, participants receive open-label treatment through Week 144.
Part 1 of the study is double-blind and at least 48 weeks in duration. Part 2 will commence once the dose is confirmed based on data through Week 48 from all participants in Part 1. In Parts 2 and 3, participants receive open-label treatment through Week 144.
Tracking Information
- NCT #
- NCT04564547
- Collaborators
- Not Provided
- Investigators
- Study Director: Medical Director Merck Sharp & Dohme Corp.
Get Well Soon